

SEQUENCE LISTING

<110> PITSON, Stuart, M.
 XIA, Pu
 MORETTI, Paul. A.
 DOBBINS, Julia R.
 VADAS, Matthew, A.
 WATTENBERG, Brian W.

<120> A Method of Modulating Cellular Activity

<130> 229752003700

<140> US 10/509,036

<141> 2003-03-28

<150> PCT/AU03/00388

<151> 2003-03-28

<150> 2003900230

<151> 2003-01-21

<150> 2002951668

<151> 2002-09-19

<150> PS1538

<151> 2002-04-05

<150> PS1621

<151> 2002-04-08

<150> PS1448

<151> 2002-03-28

<160> 14

<170> PatentIn version 3.1

<210> 1

<211> 10

<212> PRT

<213> Homo sapien

<400> 1

Lys	Thr	Pro	Ala	Ser	Pro	Val	Val	Val	Gln
1				5					10

<210> 2

<211> 14

<212> PRT

<213> Homo sapien

<400> 2

Cys Gly Ser Lys Thr Pro Ala Ser Pro Val Val Val Gln Gln
1 5 10

<210> 3
<211> 11
<212> PRT
<213> Homo sapien

<400> 3

Ser Lys Thr Pro Ala Ser Pro Val Val Val Gln
1 5 10

<210> 4
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 4

cggctgctgg cgcccatgaa c

21

<210> 5
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 5

tgtggacctc gaggctgaga agta

24

<210> 6
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 6

agtgagaagg ctcggcgcct gggggag

27

<210> 7
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
 <223> Synthetic Construct

 <400> 7

 aagagtgggc gccaaagacac 20

 <210> 8
 <211> 28
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic Construct

 <400> 8

 aagagtggga tccaaggcgc ctgcctcc 28

 <210> 9
 <211> 24
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic Construct

 <400> 9

 aagacacctg cggcgcccgt tgtg 24

 <210> 10
 <211> 24
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic Construct

 <400> 10

 acacctgccg aaccggttgt ggtc 24

 <210> 11
 <211> 19
 <212> DNA
 <213> Homo sapien

 <400> 11

 tctcactggg cagtgggtgc 19

<210> 12
 <211> 384
 <212> PRT
 <213> Homo sapien

<400> 12

Met	Asp	Pro	Ala	Gly	Gly	Pro	Arg	Gly	Val	Leu	Pro	Arg	Pro	Cys	Arg	1	5	10	15
Val	Leu	Val	Leu	Leu	Asn	Pro	Arg	Gly	Gly	Lys	Gly	Lys	Ala	Leu	Gln	20	25	30	
Leu	Phe	Arg	Ser	His	Val	Gln	Pro	Leu	Leu	Ala	Glu	Ala	Glu	Ile	Ser	35	40	45	
Phe	Thr	Leu	Met	Leu	Thr	Glu	Arg	Arg	Asn	His	Ala	Arg	Glu	Leu	Val	50	55	60	
Arg	Ser	Glu	Glu	Leu	Gly	Arg	Trp	Asp	Ala	Leu	Val	Val	Met	Ser	Gly	65	70	75	80
Asp	Gly	Leu	Met	His	Glu	Val	Val	Asn	Gly	Leu	Met	Glu	Arg	Pro	Asp	85	90	95	
Trp	Glu	Thr	Ala	Ile	Gln	Lys	Pro	Leu	Cys	Ser	Leu	Pro	Ala	Gly	Ser	100	105	110	
Gly	Asn	Ala	Leu	Ala	Ala	Ser	Leu	Asn	His	Tyr	Ala	Gly	Tyr	Glu	Gln	115	120	125	
Val	Thr	Asn	Glu	Asp	Leu	Leu	Thr	Asn	Cys	Thr	Leu	Leu	Leu	Cys	Arg	130	135	140	
Arg	Leu	Leu	Ser	Pro	Met	Asn	Leu	Leu	Ser	Leu	His	Thr	Ala	Ser	Gly	145	150	155	160
Leu	Arg	Leu	Phe	Ser	Val	Leu	Ser	Leu	Ala	Trp	Gly	Phe	Ile	Ala	Asp	165	170	175	
Val	Asp	Leu	Glu	Ser	Glu	Lys	Tyr	Arg	Arg	Leu	Gly	Glu	Met	Arg	Phe	180	185	190	
Thr	Leu	Gly	Thr	Phe	Leu	Arg	Leu	Ala	Ala	Leu	Arg	Thr	Tyr	Arg	Gly	195	200	205	
Arg	Leu	Ala	Tyr	Leu	Pro	Val	Gly	Arg	Val	Gly	Ser	Lys	Thr	Pro	Ala	210	215	220	
Ser	Pro	Val	Val	Val	Gln	Gln	Gly	Pro	Val	Asp	Ala	His	Leu	Val	Pro	225	230	235	240
Leu	Glu	Glu	Pro	Val	Pro	Ser	His	Trp	Thr	Val	Val	Pro	Asp	Glu	Asp	245	250	255	
Phe	Val	Leu	Val	Leu	Ala	Leu	Leu	His	Ser	His	Leu	Gly	Ser	Glu	Met				

260										265										270									
Phe	Ala	Ala	Pro	Met	Gly	Arg	Cys	Ala	Ala	Gly	Val	Met	His	Leu	Phe														
		275					280					285																	
Tyr	Val	Arg	Ala	Gly	Val	Ser	Arg	Ala	Met	Leu	Leu	Arg	Leu	Phe	Leu														
	290					295					300																		
Ala	Met	Glu	Lys	Gly	Arg	His	Met	Glu	Tyr	Glu	Cys	Pro	Tyr	Leu	Val														
305					310					315					320														
Tyr	Val	Pro	Val	Val	Ala	Phe	Arg	Leu	Glu	Pro	Lys	Asp	Gly	Lys	Gly														
				325					330					335															
Met	Phe	Ala	Val	Asp	Gly	Glu	Leu	Met	Val	Ser	Glu	Ala	Val	Gln	Gly														
		340						345					350																
Gln	Val	His	Pro	Asn	Tyr	Phe	Trp	Met	Val	Ser	Gly	Cys	Val	Glu	Pro														
		355					360					365																	
Pro	Pro	Ser	Trp	Lys	Pro	Gln	Gln	Met	Pro	Pro	Pro	Glu	Glu	Pro	Leu														
	370					375					380																		

<210> 13
 <211> 26
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 13

taaagcttgc caccatggtg agcaag 26

<210> 14
 <211> 29
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 14

atggatccat cttgtacagc tcgtccatg 29



United States Patent and Trademark Office

[Home](#) | [Site Index](#) | [Search](#) | [FAQ](#) | [Glossary](#) | [Guides](#) | [Contacts](#) | [eBusiness](#) | [eBiz Alerts](#) | [News](#) | [Help](#)
[Portal Home](#) | [Patents](#) | [Trademarks](#) | [Other](#) | [Sign-Off Authenticated Session](#)

Patent eBusiness

- □

- [Electronic Filing](#)
- [Patent Application Information \(PAIR\)](#)
- [Patent Ownership](#)
- [Fees](#)
- [Supplemental Resources & Support](#)

Patent Information

[Patent Guidance and General Info](#)

- [Codes, Rules & Manuals](#)
- [Employee & Office Directories](#)
- [Resources & Public Notices](#)

Patent Searches

[Patent Official Gazette](#)

- [Search Patents & Applications](#)
- [Search Biological Sequences](#)
- [Copies, Products & Services](#)

Other

- [Copyrights](#)
- [Trademarks](#)
- [Policy & Law Reports](#)

Secured Patent Application Information Retrieval

[Download](#)[Order Certified Application As Filed](#) [Or](#)

10/509,036

Method of modulating cellular activity

Select New Case	Application Data	Transaction History	Image File Wrapper	Continuity Data	Foreign Priority	Ad Attor
-----------------	------------------	---------------------	--------------------	-----------------	------------------	----------

This application is officially maintained in electronic form. To View: Click the and Print: Check the desired document(s) and click PDF.

Available Documents

Mail Room	Date	Document Code	Document Description	Docu
02-11-2009		LET.	Miscellaneous Incoming Letter	PR
02-11-2009		STATUS.LET	Request for status of Application	PR
02-11-2009		N417	EFS Acknowledgment Receipt	PR
11-13-2008		CRFD	Computer Readable Form (CRF) for Sequence Listing - Defective <i>never rec'd.</i>	PR
10-24-2008		LET.	Miscellaneous Incoming Letter	PR
10-24-2008		STATUS.LET	Request for status of Application	PR
10-24-2008		N417	EFS Acknowledgment Receipt	PR
04-24-2008		SEQ.TXT	Sequence Listing (Text File)	PR
04-24-2008		LET.	Miscellaneous Incoming Letter	PR
04-24-2008		CRFS	CRF Statement Paper and CRF are the same	PR
04-24-2008		SEQLIST	Sequence Listing	PR
03-26-2008		PET.DEC.OIPE	Petition decision routed to the OIPE to act on the decision or continue prosecution.	PR
11-13-2007		CRFD	Computer Readable Form (CRF) for Sequence Listing - Defective	PR
10-26-2007		PET.OP	Petition for review by the Office of Petitions.	PR
10-26-2007		PEFR	Applicant Response to Pre-Exam Formalities Notice	PR
10-26-2007		OATH	Oath or Declaration filed	PR
10-26-2007		ADS	Application Data Sheet	PR
10-26-2007		CRFS	CRF Statement Paper and	PR

Date	Code	Description	Status
10-26-2007	SEQLIST	<u>Sequence Listing</u>	PR
09-18-2007	ARTIFACT	<u>Artifact sheet indicating an item has been filed which cannot be scanned</u>	PR
08-28-2007	PETDEC	<u>Petition Decision</u>	PR
07-11-2007	PET.PCT	<u>Petition for review and processing by the PCT legal office.</u>	PR
05-11-2007	PET.DEC.OIPE	<u>Petition decision routed to the OIPE to act on the decision or continue prosecution.</u>	PR
04-27-2007	CRFL	<u>CRF Sequence Listing Filed</u>	PR
04-16-2007	PET.PCT	<u>Petition for review and processing by the PCT legal office.</u>	PR
07-17-2006	ABN	<u>Abandonment</u>	PR
01-17-2006	CRFD	<u>Computer Readable Form (CRF) for Sequence Listing - Defective</u>	PR
10-11-2005	LET	<u>Miscellaneous Incoming Letter</u>	PR
10-11-2005	XT/	<u>Extension of Time</u>	PR
03-08-2005	M905	<u>Notice of DO/EO Missing Requirements Mailed</u>	PR
09-27-2004	TRNA	<u>Transmittal of New Application</u>	PR
09-27-2004	SPEC	<u>Specification</u>	PR
09-27-2004	CLM	<u>Claims</u>	PR
09-27-2004	SEQLIST	<u>Sequence Listing</u>	PR
09-27-2004	ABST	<u>Abstract</u>	PR
09-27-2004	DRW	<u>Drawings-only black and white line drawings</u>	PR
09-27-2004	IMIS	<u>Miscellaneous Internal Document</u>	PR
09-27-2004	WCLM	<u>Claims Worksheet (PTO-2022)</u>	PR
09-27-2004	WFEE	<u>Fee Worksheet (PTO-875)</u>	PR
09-27-2004	WFEE	<u>Fee Worksheet (PTO-875)</u>	PR
09-27-2004	ADS	<u>Application Data Sheet</u>	PR
09-27-2004	FRPR	<u>Certified Copy of Foreign Priority Application</u>	PR
09-27-2004	FRPR	<u>Certified Copy of Foreign Priority Application</u>	PR
09-27-2004	FRPR	<u>Certified Copy of Foreign Priority Application</u>	PR
09-27-2004	FRPR	<u>Certified Copy of Foreign Priority Application</u>	PR
09-27-2004	FRPR	<u>Certified Copy of Foreign Priority Application</u>	PR
09-27-2004	371P	<u>Documents submitted with</u>	PR

		<u>371 Applications</u>	
09-27-2004	371P	<u>Documents submitted with 371 Applications</u>	PR
09-27-2004	371P	<u>Documents submitted with 371 Applications</u>	PR
09-27-2004	371P	<u>Documents submitted with 371 Applications</u>	PR
09-27-2004	371P	<u>Documents submitted with 371 Applications</u>	PR
09-27-2004	371P	<u>Documents submitted with 371 Applications</u>	PR
09-27-2004	371P	<u>Documents submitted with 371 Applications</u>	PR
09-27-2004	371P	<u>Documents submitted with 371 Applications</u>	PR
09-27-2004	371P	<u>Documents submitted with 371 Applications</u>	PR
09-27-2004	IMIS	<u>Miscellaneous Internal Document</u>	PR

If you need help:

- *Call the Patent Electronic Business Center at (866) 217-9197 (toll free questions about Patent Application Information Retrieval (PAIR)).*
- *Send general questions about USPTO programs to the USPTO Contact*
- *If you experience technical difficulties or problems with this applicatio. Business Support or call 1 800-786-9199.*

You can suggest USPTO webpages or material you would like featured on this section by E-mail to the webmaster@uspto.gov. Wl suggestions will be considered and may lead to other improvements on the web:

[Home](#) | [Site Index](#) | [Search](#) | [eBusiness](#) | [Help](#) | [Privacy Policy](#)

=====

Sequence Listing could not be accepted due to errors.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).

Reviewer: markspencer

Timestamp: [year=2008; month=11; day=13; hr=7; min=47; sec=42; ms=190;]

=====

Reviewer Comments:

<110> PITSON, Stuart, M.

XIA, Pu

MORETTI, Paul. A.

DOBBINS, Julia R.

VADAS, Matthew, A.

WATTENBERG, Brian W.

<120> A Method of Modulating Cellular Activity

<130> 229752003700

<140> US 10/509,036

<141> 2003-3-28

<150> PCT/AU03/00388

<151> 2003-3-28

<150> 2003900230

<151> 2003-1-21

* * * * *

Please change the dates for numeric identifiers <141> and <151> to the correct format, YYYY-MM-DD.

210> 7

<211> 20

<212> DNA

<213> mammalian

<400> 7

aagagtgggc gccaaagacac

20

Please correct numeric identifier <210> to have both brackets around the number.

<210> 8
<211> 28
<212> DNA
<213> mammalian
* * * * *

<210> 9
<211> 24
<212> DNA
<213> mammalian
* * * * *

<210> 10
<211> 24
<212> DNA
<213> mammalian

* * * * *
<210> 11
<211> 19
<212> DNA
<213> mammalian
* * * * *

<210> 12
<211> 384
<212> PRT
<213> mammalian
* * * * *

For SEQ ID # 1 through 12, numeric identifier <213> can only be one of three choices, "Scientific name, i.e. Genus/species, Unknown or Artificial Sequence." For all sequences using "Unknown or Artificial sequence", for numeric identifier <213>, a mandatory feature is required to explain the source of the genetic material. The feature consists of <220>, which remains blank, and <223>, which states the source of the genetic material. Suggest using "Unknown" for numeric identifier <213> and "mammalian" for numeric identifier <223> in the mandatory feature. Please make all necessary changes.

<210> 13
<211> 26
<212> DNA
<213> primers
* * * * *
<210> 14
<211> 29
<212> DNA
<213> primers
* * * * *

For SEQ ID # 13 and 14, numeric identifier <213> can only be one of three choices, "Scientific name, i.e. Genus/species, Unknown or Artificial Sequence." For all sequences using "Unknown or Artificial sequence", for numeric identifier <213>, a mandatory feature is required to explain the source of the genetic material. The feature consists of <220>, which remains blank, and <223>, which states the source of the genetic material. Suggest using "Artificial sequence" for numeric identifier <213> and "primers" for numeric identifier <223> in the mandatory feature. Please make all necessary changes.

Application No: 10509036

Version No: 1.0

Input Set:

Output Set:

Started: 2008-11-12 15:22:02.667
Finished: 2008-11-12 15:22:04.649
Elapsed: 0 hr(s) 0 min(s) 1 sec(s) 982 ms
Total Warnings: 14
Total Errors: 7
No. of SeqIDs Defined: 14
Actual SeqID Count: 13

Error code	Error Description
E 287	Invalid WIPO ST.2 date format; Use (YYYY-MM-DD) in <141>
E 287	Invalid WIPO ST.2 date format; Use (YYYY-MM-DD) in <151>
E 287	Invalid WIPO ST.2 date format; Use (YYYY-MM-DD) in <151>
W 402	Undefined organism found in <213> in SEQ ID (1)
W 402	Undefined organism found in <213> in SEQ ID (2)
W 402	Undefined organism found in <213> in SEQ ID (3)
W 402	Undefined organism found in <213> in SEQ ID (4)
W 402	Undefined organism found in <213> in SEQ ID (5)
W 402	Undefined organism found in <213> in SEQ ID (6)
W 402	Undefined organism found in <213> in SEQ ID (6)
E 212	Invalid Sequence ID Number; Expected 7 as next SeqID but skipped
W 402	Undefined organism found in <213> in SEQ ID (8)
E 249	Order Sequence Error <210> -> <212>; Expected Mandatory Tag: <211> in SEQID (9)
W 402	Undefined organism found in <213> in SEQ ID (9)
W 402	Undefined organism found in <213> in SEQ ID (10)
W 402	Undefined organism found in <213> in SEQ ID (11)
W 402	Undefined organism found in <213> in SEQ ID (12)
W 402	Undefined organism found in <213> in SEQ ID (13)
W 402	Undefined organism found in <213> in SEQ ID (14)

Input Set:

Output Set:

Started: 2008-11-12 15:22:02.667

Finished: 2008-11-12 15:22:04.649

Elapsed: 0 hr(s) 0 min(s) 1 sec(s) 982 ms

Total Warnings: 14

Total Errors: 7

No. of SeqIDs Defined: 14

Actual SeqID Count: 13

Error code	Error Description
E 252	Calc# of Seq. differs from actual; 14 seqIds defined; count=13
E 250	Structural Validation Error; Sequence listing may not be indexable

SEQUENCE LISTING

<110> PITSON, Stuart, M.

XIA, Pu

MORETTI, Paul. A.

DOBBINS, Julia R.

VADAS, Matthew, A.

WATTENBERG, Brian W.

<120> A Method of Modulating Cellular Activity

<130> 229752003700

<140> US 10/509,036

<141> 2003-3-28

<150> PCT/AU03/00388

<151> 2003-3-28

<150> 2003900230

<151> 2003-1-21

<150> 2002951668

<151> 2002-09-19

<150> PS1538

<151> 2002-04-05

<150> PS1621

<151> 2002-04-08

<150> PS1448

<151> 2002-03-28

<160> 14

<170> PatentIn version 3.1

<210> 1

<211> 10

<212> PRT

<213> mammalian

<400> 1

Lys Thr Pro Ala Ser Pro Val Val Val Gln

1 5 10

<210> 2

<211> 14

<212> PRT

<213> mammalian

<400> 2

Cys Gly Ser Lys Thr Pro Ala Ser Pro Val Val Val Gln Gln

1 5 10

<210> 3
<211> 11
<212> PRT
<213> mammalian

<400> 3

Ser Lys Thr Pro Ala Ser Pro Val Val Val Gln

1 5 10

<210> 4
<211> 21
<212> DNA
<213> mammalian

<400> 4

cggtctgtgg cgcccatgaa c 21

<210> 5
<211> 24
<212> DNA
<213> mammalian

<400> 5

tgtggacctc gaggtgaga agta 24

<210> 6
<211> 27
<212> DNA
<213> mammalian

<400> 6

agtgagaagg ctgggcgcct gggggag 27

210> 7
<211> 20
<212> DNA
<213> mammalian

<400> 7

aagagtgggc gccaaacac 20

<210> 8
<211> 28
<212> DNA
<213> mammalian

<400> 8

aagagtggga tccaaggcgc ctgcctcc 28

<210> 9

<211> 24

<212> DNA

<213> mammalian

<400> 9

aagacacctg cggcgcccgt tgtg 24

<210> 10

<211> 24

<212> DNA

<213> mammalian

<400> 10

acacctgccg aaccggttgt ggtc 24

<210> 11

<211> 19

<212> DNA

<213> mammalian

<400> 11

tctcactggg cagtgggtgc 19

<210> 12

<211> 384

<212> PRT

<213> mammalian

<400> 12

Met Asp Pro Ala Gly Gly Pro Arg Gly Val Leu Pro Arg Pro Cys Arg
1 5 10 15

Val Leu Val Leu Leu Asn Pro Arg Gly Gly Lys Gly Lys Ala Leu Gln
20 25 30

Leu Phe Arg Ser His Val Gln Pro Leu Leu Ala Glu Ala Glu Ile Ser
35 40 45

Phe Thr Leu Met Leu Thr Glu Arg Arg Asn His Ala Arg Glu Leu Val
50 55 60

Arg Ser Glu Glu Leu Gly Arg Trp Asp Ala Leu Val Val Met Ser Gly
65 70 75 80

Asp Gly Leu Met His Glu Val Val Asn Gly Leu Met Glu Arg Pro Asp	85	90	95
Trp Glu Thr Ala Ile Gln Lys Pro Leu Cys Ser Leu Pro Ala Gly Ser	100	105	110
Gly Asn Ala Leu Ala Ala Ser Leu Asn His Tyr Ala Gly Tyr Glu Gln	115	120	125
Val Thr Asn Glu Asp Leu Leu Thr Asn Cys Thr Leu Leu Leu Cys Arg	130	135	140
Arg Leu Leu Ser Pro Met Asn Leu Leu Ser Leu His Thr Ala Ser Gly	145	150	155
Leu Arg Leu Phe Ser Val Leu Ser Leu Ala Trp Gly Phe Ile Ala Asp	165	170	175
Val Asp Leu Glu Ser Glu Lys Tyr Arg Arg Leu Gly Glu Met Arg Phe	180	185	190
Thr Leu Gly Thr Phe Leu Arg Leu Ala Ala Leu Arg Thr Tyr Arg Gly	195	200	205
Arg Leu Ala Tyr Leu Pro Val Gly Arg Val Gly Ser Lys Thr Pro Ala	210	215	220
Ser Pro Val Val Val Gln Gln Gly Pro Val Asp Ala His Leu Val Pro	225	230	235
Leu Glu Glu Pro Val Pro Ser His Trp Thr Val Val Pro Asp Glu Asp	245	250	255
Phe Val Leu Val Leu Ala Leu Leu His Ser His Leu Gly Ser Glu Met	260	265	270
Phe Ala Ala Pro Met Gly Arg Cys Ala Ala Gly Val Met His Leu Phe	275	280	285
Tyr Val Arg Ala Gly Val Ser Arg Ala Met Leu Leu Arg Leu Phe Leu	290	295	300
Ala Met Glu Lys Gly Arg His Met Glu Tyr Glu Cys Pro Tyr Leu Val	305	310	315
Tyr Val Pro Val Val Ala Phe Arg Leu Glu Pro Lys Asp Gly Lys Gly	325	330	335
Met Phe Ala Val Asp Gly Glu Leu Met Val Ser Glu Ala Val Gln Gly	340	345	350
Gln Val His Pro Asn Tyr Phe Trp Met Val Ser Gly Cys Val Glu Pro	355	360	365
Pro Pro Ser Trp Lys Pro Gln Gln Met Pro Pro Pro Glu Glu Pro Leu	370	375	380

<210> 13
<211> 26
<212> DNA
<213> primers

<400> 13

taaagcttgc caccatggtg agcaag 26

<210> 14
<211> 29
<212> DNA
<213> primers

<400> 14

atggatccat cttgtacagc tcgtccatg 29

